These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 8879972)

  • 1. Treatment of HIV infection. Tolerability of commonly used antiretroviral agents.
    Notermans DW; van Leeuwen R; Lange JM
    Drug Saf; 1996 Sep; 15(3):176-87. PubMed ID: 8879972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Didanosine: an updated review of its use in HIV infection.
    Perry CM; Noble S
    Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
    Barry M; Mulcahy F; Merry C; Gibbons S; Back D
    Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [AIDS; new developments. II. Treatment of HIV infection].
    Borleffs JC; Esseveld F; Hoepelman IM; Boucher CA
    Ned Tijdschr Geneeskd; 1997 May; 141(21):1036-43. PubMed ID: 9340560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination antiretroviral therapy for HIV infection.
    Maenza J; Flexner C
    Am Fam Physician; 1998 Jun; 57(11):2789-98. PubMed ID: 9636341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
    Adkins JC; Peters DH; Faulds D
    Drugs; 1997 Jun; 53(6):1054-80. PubMed ID: 9179531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection.
    Noble S; Faulds D
    Drugs; 1996 Jul; 52(1):93-112. PubMed ID: 8799687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New antiretrovirals and new combinations.
    Havlir DV; Lange JM
    AIDS; 1998; 12 Suppl A():S165-74. PubMed ID: 9632999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of antiretrovirals in pregnant women.
    Mirochnick M; Capparelli E
    Clin Pharmacokinet; 2004; 43(15):1071-87. PubMed ID: 15568888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretrovirals.
    Temesgen Z; Wright AJ
    Mayo Clin Proc; 1999 Dec; 74(12):1284-301. PubMed ID: 10593358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity of antiretroviral agents.
    Struble KA; Pratt RD; Gitterman SR
    Am J Med; 1997 May; 102(5B):65-7; discussion 68-9. PubMed ID: 9845500
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
    Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
    De Clercq E
    Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.
    Arendt G; von Giesen HJ; Hefter H; Theisen A
    AIDS; 2001 Mar; 15(4):493-500. PubMed ID: 11242146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral Therapy in the Real World : Population-Based Pharmacoeconomic Analysis of Administration of Anti-HIV Regimens to 990 Patients.
    Sabbatani S; Manfredi R; Biagetti C; Chiodo F
    Clin Drug Investig; 2005; 25(8):527-35. PubMed ID: 17532696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.
    Perry CM; Balfour JA
    Drugs; 1996 Dec; 52(6):928-62. PubMed ID: 8957161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.